Former US Food and Drug Administration (FDA) Commissioner Andrew Von Eschenbach has an op-ed in the 14 February edition of the Wall Street Journal in which he calls for some drugs to be approved based on only premarket indications of safety, with testing on efficacy and effectiveness to be left for postmarket studies. "[T]here is a growing recognition-at the agency, in the industry and among patients' groups-that it is at serious risk of falling behind its core res...